References
- Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the US: results from the 2019 National Survey on Drug Use and Health; 2020. https://www.samhsa.gov/data/report/2019-nsduh-annual-national-report. Accessed January 24, 2021.
- National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder save Lives. Washington, DC: The National Academies Press.
- 21 United States Code Section 823; 2021. Available from: https://uscode.house.gov/browse/prelim@title21&edition=prelim. Accessed April 4, 2022.
- American Society of Addiction Medicine. National practice guideline for the treatment of opioid use disorder, 20202 focused update; December 19, 2019. https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2. Accessed February 28, 2021.
- Spetz J, Toretsky C, Chapman S, Phoenix B, Tierney M. Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA 2019;321(14):1407–1408.
- Buprenorphine Practitioner Locator. Substance abuse and mental health services administration. https://www.samhsa.gov/medication-assisted-treatment/practitioner-program-data/treatment-practitioner-locator. Accessed February 28, 2021.
- Opioid Treatment Program Director. Substance abuse and mental health services administration. https://dpt2.samhsa.gov/treatment/directory.aspx. Accessed February 28, 2021.
- US Dept. of Health & Human Services. Public listing status of DATA-waivered providers: DATA Brief; June 3, 2019. https://aspe.hhs.gov/basic-report/public-listing-status-data-waivered-providers-data-brief. Accessed February 28, 2021.
- Buprenorphine Practitioner Resources and Information. Substance abuse and mental health services administration; August 19, 2020. Available from: https://www.samhsa.gov/medication-assisted-treatment/practitioner-resources. Accessed February 28, 2021
- Ghertner R, Ali MM. Increases in providers with buprenorphine waivers in the US from 2016 to 2019. PS. 2020;71(9):971–971.
- Flavin LILA, Malowney M, Patel NA, et al. Availability of buprenorphine treatment in the 10 states with the highest drug overdose death rates in the US. J Psychiat Pract. 2020;26(1):17–22.
- US Dept. Health & Human Services. Announcement of practice guidelines for the administration of buprenorphine for treating opioid use disorder; January 12, 2021. https://www.hhs.gov/sites/default/files/mat-physician-practice-guidelines.pdf. Accessed February 28, 2021.
- Berk J. To help providers fight the opioid epidemic, “X the X wavier”. Health Affairs Blog; March 5, 2019. Available from: doi:10.1377/forefront.20190301.79453
- Lagisetty PA, Bohnert A. Role of an accurate treatment locator and cash-only practices in access to buprenorphine for opioid use disorders. Ann Intern Med. 2019;171(1):58.
- Stephenson J. CDC warns of surge in drug overdose deaths during COVID-19. JAMA Health Forum. 2021;2(1):e210001.
- Rural-Urban Commuting Area Codes (RUCAs). Rural Health Research Center. Available from: http://depts.washington.edu/uwruca/index.php. Accessed April 4, 2022.
- Beetham T, Saloner B, Wakeman SE, et al. Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study. Ann Intern Med. 2019;171(1):1–9.